



H1 Financial Results and Business Update Webcast and Conference Call



Important notice and disclaimer

This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities in the Company or any other entity. By reviewing this document, you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you and will not use this information in relation to any investment decision.

This document and its contents may not be reproduced, redistributed, published or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose. Failure to comply with these restrictions may constitute a violation of applicable securities laws. By accepting and reading this document, you will be deemed to agree not to disclose, reproduce or otherwise distribute any information contained herein.

Certain information contained in this document has been obtained from published and non-published sources prepared by third parties. While such information is believed to be reliable for the purposes used herein, none of the Company or its affiliates, directors, officers, employees, members, partners, shareholders or agents make any representation or warranty with respect to or assume any responsibility for the accuracy of such information, and such information has not been independently verified by the Company.

Certain statements contained in this document constitute forward-looking statements, estimates, predictions, influences and projections which are subject to risks and uncertainties and may reflect various assumptions, which may or may not prove to be correct. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, results of operations, liquidity, business strategy, management plans and objectives for future operations. In particular, the words “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” or other similar expressions are intended to identify forward-looking statements. Forward-looking statements appear in a number of places in this presentation and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to of various risk factors and uncertainties including without limitation in relation to: the effectiveness of our main product candidate, and our ability to commercialize it if the regulatory approval is obtained; our ability to explore other potential fields of application of our product candidates and benefits of combination therapies between our product candidates and other products; our ability to compete and conduct our business in the future; our ability to expend our limited resources and to obtain funding for our operations necessary to continue as a going concern or to complete further development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. Moreover, we operate in an evolving environment. Thus, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events or otherwise, except as required by applicable law.

Agenda

1. H1 2026 Overview

Julia Neugebauer, PhD
Chief Operating Officer



2. Understanding Varoglutamstat's MoA

Michael Schaeffer, PhD
Chief Business Officer



3. Advancing Strategic Priorities

Frank Weber, MD
Chief Executive Officer



4. Financial Results

Marcus Irsfeld
Chief Financial Officer



5. Q&A

H1 2026 Overview

Julia Neugebauer
COO

Growing momentum and robust body of evidence for varoglutamstat in kidney disease

Advancing strategic priorities

- ◆ Currently in advanced term sheet negotiations for a potential licensing agreement for varoglutamstat in kidney disease¹

Strong clinical & scientific evidence

- ◆ Presented at key international kidney conference in Japan
- ◆ Further elucidated varoglutamstat MoA: newly identified roles in collagen maturation, ROS generation, endothelial function

Financials

- ◆ Cash runway into Q4 2026
- ◆ Actively exploring partnership / funding options

Understanding Varoglutamstat's MoA

Michael Schaeffer
CBO

Understanding varoglutamstat's unique mechanism of action

Varoglutamstat

Reduction of pro-inflammatory and pro-fibrotic signaling

by destabilizing key molecules such as chemokines and reducing myofibroblast generation/activation

Reduction of tubulointerstitial fibrosis and glomerulosclerosis

by affecting maturation and stability of key ECM components like collagens


Improvement of endothelial cell function

via activation of HIF pathways and upregulation of VEGF

- Reversal of capillary rarefaction
→ improved blood supply
- Prevention of endothelial cell death
- Vascular stabilization

New


Varoglutamstat in kidney disease: counteracting loss of kidney function at multiple levels



Advancing Strategic Priorities

Frank Weber
CEO

Progressing strategic priorities to secure development of varoglutamstat



H1 2026 Financial Results

Marcus Irsfeld
CFO

Key financial figures

In €k	Six months ended Jun 30, 2026	Six months ended Jun 30, 2025
Revenue	0	0
Research & Development expenses	(1,659)	(2,768)
General & Administrative expenses	(1,732)	(2,755)
Net loss for the period	(3,388)	(5,473)

In €k	Jun 30, 2026	Dec 31, 2025
Cash & cash equivalents	2,446	5,619
Financial assets	98	33

- ◆ Cash runway maintained into Q4 2026; continue to actively explore strategic and financing options to strengthen financial position

Summary

Frank Weber
CEO

Developing new therapies with the aim of preserving kidney function and preventing progression to kidney failure



Significant unmet need in diabetic kidney disease (DKD)

~1.5M patients in U.S. and ~2.4M patients in EU with DKD stage 3b/4

Primary goal of new treatments is to stabilize / improve kidney function



Compelling data with lead program varoglutamstat

Differentiated MOA targeting pro-inflammatory & pro-fibrotic pathways

First oral agent to show improvement and long-term stabilization of kidney function¹



Attractive opportunity with defined value-creation steps

Substantial market creating blockbuster potential

Advanced partnership negotiations ongoing

Q&A



Vivoryon Therapeutics N.V.

Halle (Saale)
Weinbergweg 22
06120 Halle (Saale), Germany

Munich
Franz-Josef-Delonge-Str. 5
81249 München, Germany

IR@vivoryon.com

www.vivoryon.com